Henlius Reports Positive Results of HLX04 (biosimilar- bevacizumab) in P-III Trial for Metastatic Colorectal Cancer
Shots:
- HLX04 is a biosimilar that binds to vascular endothelial growth factor (VEGF) for inhibiting angiogenesis where VEGF acts for promoting growth of blood vessels can inhibit tumor angiogenesis further preventing tumor growth or metastasis. The biosimilar was developed under Chinese biosimilar guideline
- The P-III HLX04-mCRC03 trial involves assessing of HLX04 (biosimilar- bevacizumab) or Avastin (bevacizumab) in combination with oxaliplatin and fluoropyrimidine-based CT (XELOX or mFOLFOX6) for 1L patients with mCRC and showed bioequivalent to the Avastin in terms of PK and AEs
- The product has also shown bio-similarity in product quality- pharmacology- PK- PD- toxicology and immunogenicity in analytical studies- preclinical studies and P-I clinical study- Presented at Chinese Society of Clinical Oncology
Click here to read full press release/ article | Ref: Henlius | Image: Henlius
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com